Cytovance Biologics entered a strategic collaboration with Alcami Corp. to expand its large molecule biologic manufacturing and sterile fill finish offering. Cytovance aims to overcome development and manufacturing obstacles by fine-tuning processes to help drug developers. 
 
With the addition of Alcami’s sterile fill-finish spaces and individual manufacturing and filling lines, Cytovance customers will now have the option to transition their bulk product to a vetted cGMP partner for advanced clinical and commercial production and packaging. Alcami’s offering includes formulation, release, and stability testing, vial and syringe filling, and advanced cGMP biostorage options that have already supported the successful launch of over 50 commercial products. The two companies currently coordinating respective manufacturing processes and quality systems. 
 
Cytovance CCO, Axel Schleyer, said, “Our team is very excited to combine Alcami’s expertise in liquid and lyophilization sterile filling, packaging, and labeling with our bulk drug substance development and manufacturing services. Our shared cultures of quality and ingenuity make this a winning combination to support life-changing drugs every step on the path to patient, from early development to commercial supply!”
 
“We are proud to work alongside the team at Cytovance Biologics to deliver unrivaled expertise in high-quality fill-finish operations during this pivotal moment in complex large molecule drug development. Our combined 77 years of serving the life science industry promises our shared customers the utmost commitment to pharmacological product quality, ultimately getting new drug products to patients faster,” said Alcami CEO William Humphries.